REMEDIUM

Since a partially unfavourable epidemiological situation persists, the Russian pharmaceutical market remains one of the most steadily growing in terms of roubles. Feverish demand for drugs, enhancement of the role of the public segment, increase in importance and speed of adoption of legislative initiatives – all these factors have a significant impact on both the dynamics and conditions of the broader market, becoming not only a strength test for the pharmaceutical industry, but also a chance to implement new opportunities.

Among other things, 2020 with all its challenges exposed high Russian pharma dependence on API imports, and showed a number of problems that domestic manufacturers may encounter.

За последние 20 лет произошел настоящий прорыв в лечении рака молочной железы (РМЖ), в результате которого значительно увеличилась продолжительность жизни больных и улучшилось ее качество. О том, как новые препараты изменили парадигму лечения РМЖ, мы решили узнать у Евгения ИМЯНИТОВА, руководителя референс-центра и заведующего отделом биологии опухолевого роста ФГБУ «НМИЦ онкологии им. Н.Н. Петрова», члена-корреспондента РАН, профессора, д.м.н.

A novel cornavirus infection declared by WHO a COVID-19 pandemic has set the task of raising funds to address the challenge posed by the novel coronavirus SARS-Cov-2 against civilization. The design of drugs with antiviral activity against the novel coronavirus has resulted in the development of several drug candidates. Remdesivir developed by the American company Gilead Sciences Inc. has become one of the first drug, upon which the decision on using it as a pharmacotherapeutic agent was reached. Initially, the drug was created in 2009 for the treatment of other viral diseases but did not show the expected activity. The further development and assessment of pharmacological activity was carried out with the encouragement of public investment in conjunction with and under guidance of the USA Department of Defence and some university laboratories.The findings of clinical trials conducted in different countries have shown the future-oriented outlook for remdesivir for the treatment of patients with COVID-19, which, however, left WHO underwhelmed, as a result it did not recommend the drug as a pharmacotherapy for novel coronavirus infection. After an expert analysis, the Ministry of Health of the Russian Federation included remdesivir in the list of drugs that can be used in the treatment of COVID-19 along with other drugs. The study of the features and circumstances of the launch of remdesivir to the pharmaceutical market allows us to come ever closer to the answer to the fundamental question of the 21st century: SARS-Cov-2 is a design of nature or the result of purposeful anthropogenic activity.

Over the past two decades we have seen a breakthrough in the study of gout, one of the most common inflammatory joint diseases representing a great challenge for both patients and the healthcare system. The international and Russian guidelines for the treatment of patients with gout have been improved and updated in the light of scientific achievements and their successful application in real practice. For example, the guidelines of the American College of Rheumatology (ACR) that discuss new strategies for managing patients with gout were changed and added in 2020 [1].

Anemia is the most frequent systemic complication and extraintestinal manifestation of gastrointestinal diseases, which is likely to be a unique example of chronic iron deficiency combined with anemia of chronic disease. In this case, anemia is not just a laboratory marker, but a complication that requires appropriate diagnostic and therapeutic approaches. At the same time, many global clinical guidelines, including gastroenterological ones, do not contain up-to-date scientific information on the most effective drugs with a favourable safety profile – intravenous iron preparations, which can be used both to manage anemia and replenish iron stores. The evidence base on these drugs is growing fast due to qualitative studies as well as systematic reviews and meta-analyses.

Регулярный мониторинг уровня глюкозы в крови является важнейшей задачей для всех больных сахарным диабетом. Особенно остро данная проблема стоит на сегодняшний день, когда больные с СД отнесены к категории риска тяжелого течения COVID-19 [1]. На российском рынке представлен целый ряд современных и удобных в использовании глюкометров, позволяющих эффективно решать эту задачу и держать СД под контролем даже в непростых эпидемиологических условиях, когда возможность посещения врача может быть ограниченна.

The problem of wound disinfection does not lose its relevance over time and affects a number of areas of medicine. Despite the obvious progress in the creation of disinfectant drugs (DD), the issue of destroying infectious agents on the damaged skin is currently quite acute.

Маркировка охватывает все больше отраслей рынка. Первого мая стартовал пилотный проект по кодированию биологически активных добавок (ПП №6731). Он продлится до 31 августа 2022 г. А 1 июля перестает действовать упрощенный механизм «обратной приемки лекарств»2, введенный в связи с техническими сбоями в системе МДЛП и возникшей в связи с этим дефектуры лекарств.

The gross profit is one of the quantitative criteria of business activity in absolute terms, which can be used to assess the results and efficiency of the main production activities of enterprises. The ranking will be based not only on the absolute indicators of pharmaceutical manufacturers, such as the gross profit volume of enterprises, but also on relative or specific indicators – the trends in these volumes. The manufacturers ranking will be determined using one of the mathematical methods, which is called the sum of rankings. The ranking was prepared using the state accounting data of the top 90 pharmaceutical manufacturers. It should be noted that only profitable industry enterprises were included in the ranking.

Проблема преемственности знаний и передачи высоких стандартов в области соблюдения требований GMP при производстве лекарственных препаратов и проведении инспекций фармзаводов теперь решена. В Москве открыта Евразийская академия надлежащих практик, которая поможет привести к общему знаменателю подходы к инспектированию на едином рынке ЕАЭС. Этот проект позволит удовлетворить высокую потребность в повышении квалификации не только GMP-инспектората, но и всех участников рынка.

По итогам марта 2021 г. в сегменте фармацевтической рекламы в категории «Лекарственные препараты и биологически активные добавки» (ЛП и БАД) на топ-20 рекламодателей суммарно по всем типам СМИ пришлось более 107 тыс. выходов рекламы, а на топ-20 марок ЛП и БАД – более 40 тыс. выходов.